WAYNE, PA & UTRECHT, Netherlands — NanoCell Therapeutics, Inc. announced the appointment of Prof. Zoltán Ivics, PhD, Jens Hasskarl, MD, PhD, and Jake Brenner, MD, PhD, to its Scientific Advisory Board, strengthening the company’s expertise across gene therapy research, development, and clinical translation.
“Drs. Ivics, Hasskarl, and Brenner bring expertise that spans the entire gene therapy development spectrum, from foundational research through commercial success to clinical practice,” said Dr. Maurits Geerlings, CEO and President of NanoCell. “Our team looks forward to working closely with them as we advance NanoCell toward its next milestones.”
Prof. Ivics, a molecular biologist and gene therapy innovator, serves as Professor at the Institute for Clinical Immunology at the University of Leipzig and Head of the Department for Clinical Gene Transfer at the Fraunhofer Institute for Cell Therapy and Immunology in Germany. He is best known for reconstructing the Sleeping Beauty transposon, recognized as “Molecule of the Year” in 2009, a breakthrough that helped pave the way for modern gene therapy applications. Ivics has authored more than 190 scientific publications, holds 12 patents, and is president of the German Society of Gene Therapy.
Dr. Hasskarl, a board-certified hematologist and oncologist, brings more than 20 years of clinical and regulatory leadership experience in cell and gene therapy. He has held senior roles at Priothera, Advesya, Tigen Pharma, Celgene/BMS, and Novartis, contributing to the development and approval of therapies including Kymriah, Breyanzi, and Abecma. He earned his medical degree summa cum laude from Heidelberg University and holds a diploma in health economics.
Dr. Brenner, an assistant professor and attending physician at the University of Pennsylvania, divides his time between intensive care practice and running a bioengineering laboratory focused on mRNA and DNA lipid nanoparticle therapies for critical illnesses, including stroke. He earned his MD and PhD from Stanford University, where he also completed his residency.
The appointments bolster NanoCell’s scientific and clinical depth as it advances toward first-in-human studies. Dr. Ivics contributes pioneering expertise in transposon technology, Dr. Hasskarl provides extensive experience in late-stage clinical development and regulatory strategy, and Dr. Brenner brings translational and patient-centered insight from the front lines of academic medicine.
NanoCell also acknowledged Perry Hackett, PhD, for his years of service and contributions to the company’s Scientific Advisory Board.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.